Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Glycerol Phenylbutyrate (Ravicti) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.
OVERVIEW | |
---|---|
Interface: | Ovid |
Databases: | Embase 1974 to present |
Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to present | |
Note: Subject headings have been customized for each database. Duplicates between databases were removed in Ovid | |
Date of Search: | September 22, 2016 |
Alerts: | Weekly search updates until February 15, 2017 |
Study Types: | No search filters were applied |
Limits: | No date or language limits were used |
Conference abstracts were excluded | |
SYNTAX GUIDE | |
/ | At the end of a phrase, searches the phrase as a subject heading |
MeSH | Medical Subject Heading |
* | Before a word, indicates that the marked subject heading is a primary topic; or, after a word, a truncation symbol (wildcard) to retrieve plurals or varying endings |
.ti | Title |
.ab | Abstract |
.ot | Original title |
.hw | Heading word; usually includes subject headings and controlled vocabulary |
.kf | Author keyword heading word (MEDLINE) |
.kw | Author keyword (Embase) |
.pt | Publication type |
.rn | CAS registry number |
.nm | Name of substance word |
ppez | Ovid database code; Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) |
oemezd | Ovid database code; Embase 1974 to present, updated daily |
MULTI-DATABASE STRATEGY | |
---|---|
# | Strategy |
1 | (ravicti* or glycerol phenylbutyrate or “glycerol tri(4 phenylbutyrate)” or “glycerol tris(4 phenylbutanoate)” or “glycerol tris(4 phenylbutyrate)” or “glyceryl tri(4 phenylbutyrate)” or “glyceryl tris(4 phenylbutyrate)” or “tris(4-phenylbutyryl)glycerol” or hpn 100 or hpn100 or “propane 1,2,3 triyl tris(4 phenylbutanoate)” or ZH6F1VCV7B or 611168-24-2).ti,ab,ot,kf,hw,rn,nm. |
2 | 1 use ppez |
3 | glycerol phenylbutyrate/ |
4 | (ravicti* or glycerol phenylbutyrate or “glycerol tri(4 phenylbutyrate)” or “glycerol tris(4 phenylbutanoate)” or “glycerol tris(4 phenylbutyrate)” or “glyceryl tri(4 phenylbutyrate)” or “glyceryl tris(4 phenylbutyrate)” or “tris(4-phenylbutyryl)glycerol” or hpn 100 or hpn100 or “propane 1,2,3 triyl tris(4 phenylbutanoate)” or ZH6F1VCV7B or 611168-24-2).ti,ab,ot,kw. |
5 | or/3–4 |
6 | 5 use oemezd |
7 | 6 not conference abstract.pt. |
8 | 2 or 7 |
9 | remove duplicates from 8 |
OTHER DATABASES | |
---|---|
PubMed | A limited PubMed search was performed to capture records not found in MEDLINE. Same MeSH, keywords, limits, and study types used as per MEDLINE search, with appropriate syntax used. |
Trial registries (Clinicaltrials.gov and others) | Same keywords, limits used as per MEDLINE search. |
Grey Literature
Dates for Search: | September 2016 |
Keywords: | Ravicti, glycerol phenylbutyrate urea cycle disorder, urea cycle disorders |
Limits: | No date or language limits used |
Relevant websites from the following sections of the CADTH grey literature checklist Grey Matters: a practical tool for searching health-related grey literature (https://www.cadth.ca/grey-matters) were searched:
- Health Technology Assessment Agencies
- Health Economics
- Clinical Practice Guidelines
- Drug and Device Regulatory Approvals
- Advisories and Warnings
- Drug Class Reviews
- Databases (free)
- Internet Search.
- LITERATURE SEARCH STRATEGY - Glycerol Phenylbutyrate (Ravicti)LITERATURE SEARCH STRATEGY - Glycerol Phenylbutyrate (Ravicti)
- SUMMARY OF EFFICACY AND SAFETY RESULTS IN THREE SHORT-TERM, NON-RANDOMIZED STUDI...SUMMARY OF EFFICACY AND SAFETY RESULTS IN THREE SHORT-TERM, NON-RANDOMIZED STUDIES: UP 1204-003, HPN-100-005, AND HPN-100-012 - Glycerol Phenylbutyrate (Ravicti)
- DETAILED OUTCOME DATA - Ustekinumab (Stelara)DETAILED OUTCOME DATA - Ustekinumab (Stelara)
- CONCLUSIONS - Glycerol Phenylbutyrate (Ravicti)CONCLUSIONS - Glycerol Phenylbutyrate (Ravicti)
- CADTH COMMON DRUG REVIEW REANALYSES - Glycerol Phenylbutyrate (Ravicti)CADTH COMMON DRUG REVIEW REANALYSES - Glycerol Phenylbutyrate (Ravicti)
Your browsing activity is empty.
Activity recording is turned off.
See more...